CL2013003805A1 - Combinación que comprende un primer agente que es un inhibidor de cinasa 4 dependiente de ciclina o cinasa 6 dependiente de ciclina (cdk4/6) de fórmula a y un segundo agente que es un inhibidor de pi3 cinasa de fórmula b1 o b2; uso para tratar cáncer. - Google Patents

Combinación que comprende un primer agente que es un inhibidor de cinasa 4 dependiente de ciclina o cinasa 6 dependiente de ciclina (cdk4/6) de fórmula a y un segundo agente que es un inhibidor de pi3 cinasa de fórmula b1 o b2; uso para tratar cáncer.

Info

Publication number: CL2013003805A1
Authority: CL; Chile
Prior art keywords: agent; formula; inhibitor; cyclin dependent; kinase
Prior art date: 2011-07-01

Application number

CL2013003805A

Other languages

English (en)

Inventor

Yan Chen

Sunkyu Kim

Shivang Doshi

Kristy Haas

Steven Kovats

Alan Xizhong Huang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-01

Filing date

2013-12-31

Publication date

2014-08-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-12-31 Application filed by Novartis Ag filed Critical Novartis Ag

2014-08-08 Publication of CL2013003805A1 publication Critical patent/CL2013003805A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2013003805A 2011-07-01 2013-12-31 Combinación que comprende un primer agente que es un inhibidor de cinasa 4 dependiente de ciclina o cinasa 6 dependiente de ciclina (cdk4/6) de fórmula a y un segundo agente que es un inhibidor de pi3 cinasa de fórmula b1 o b2; uso para tratar cáncer. CL2013003805A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161503642P	2011-07-01	2011-07-01

Publications (1)

Publication Number	Publication Date
CL2013003805A1 true CL2013003805A1 (es)	2014-08-08

Family

ID=46513871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003805A CL2013003805A1 (es)	2011-07-01	2013-12-31	Combinación que comprende un primer agente que es un inhibidor de cinasa 4 dependiente de ciclina o cinasa 6 dependiente de ciclina (cdk4/6) de fórmula a y un segundo agente que es un inhibidor de pi3 cinasa de fórmula b1 o b2; uso para tratar cáncer.

Country Status (23)

Country	Link
US (2)	US9271988B2 (es)
EP (1)	EP2726074B1 (es)
JP (2)	JP5832647B2 (es)
KR (1)	KR20140040770A (es)
CN (1)	CN103635189B (es)
AU (3)	AU2012279117A1 (es)
BR (1)	BR112013033940A2 (es)
CA (1)	CA2840754A1 (es)
CL (1)	CL2013003805A1 (es)
CO (1)	CO6842016A2 (es)
EA (1)	EA030465B1 (es)
ES (1)	ES2676180T3 (es)
GT (1)	GT201300320A (es)
IL (1)	IL229876B (es)
MA (1)	MA35210B1 (es)
MX (1)	MX359406B (es)
MY (1)	MY161237A (es)
PE (1)	PE20141381A1 (es)
PH (1)	PH12013502697A1 (es)
TN (1)	TN2013000508A1 (es)
UA (1)	UA114178C2 (es)
WO (1)	WO2013006532A1 (es)
ZA (1)	ZA201309241B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MX358640B (es)	2008-01-04	2018-08-29	Intellikine Llc	Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
TWI546305B (zh)	2011-01-10	2016-08-21	英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
JP5832647B2 (ja) *	2011-07-01	2015-12-16	ノバルティスアーゲー	がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
KR20150002623A (ko) *	2012-03-30	2015-01-07	노파르티스 아게	신경모세포종, 유잉 육종 또는 횡문근육종의 치료에 사용하기 위한 화합물
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014022830A2 (en)	2012-08-03	2014-02-06	Foundation Medicine, Inc.	Human papilloma virus as predictor of cancer prognosis
CN105102000B (zh)	2012-11-01	2021-10-22	无限药品公司	使用pi3激酶亚型调节剂的癌症疗法
EP3251673A1 (en)	2012-12-13	2017-12-06	IP Gesellschaft für Management mbH	Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN105407723A (zh)	2013-03-15	2016-03-16	G1治疗公司	高效的抗赘生剂和抗增生剂
WO2014144326A1 (en)	2013-03-15	2014-09-18	G1 Therapeutics, Inc.	Transient protection of normal cells during chemotherapy
MX378263B (es)	2013-08-14	2025-03-10	Novartis Ag	Terapia de combinación para el tratamiento del cáncer.
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
US20150320754A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
US20150297606A1 (en)	2014-04-17	2015-10-22	G1 Therapeutics, Inc.	Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
WO2016040858A1 (en) *	2014-09-12	2016-03-17	G1 Therapeutics, Inc.	Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en)	2014-09-12	2016-03-17	G1 Therapeutics, Inc.	Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN111848643A (zh)	2015-07-02	2020-10-30	豪夫迈·罗氏有限公司	苯并氧氮杂*噁唑烷酮化合物及其使用方法
PE20211775A1 (es)	2015-07-02	2021-09-08	Hoffmann La Roche	Compuestos de benzoxacepina oxazolidinona y metodos de uso
CN108348514A (zh) *	2015-08-28	2018-07-31	诺华股份有限公司	含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
WO2017172734A1 (en)	2016-03-29	2017-10-05	Mayo Foundation For Medical Education And Research	Treating cancer metastasis
EP3474856B1 (en)	2016-06-24	2022-09-14	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2018017410A1 (en)	2016-07-22	2018-01-25	Eli Lilly And Company	Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018081211A1 (en) *	2016-10-26	2018-05-03	Li George Y	Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
WO2018106729A1 (en)	2016-12-05	2018-06-14	G1 Therapeutics, Inc.	Preservation of immune response during chemotherapy regimens
US11395821B2 (en)	2017-01-30	2022-07-26	G1 Therapeutics, Inc.	Treatment of EGFR-driven cancer with fewer side effects
WO2019136451A1 (en)	2018-01-08	2019-07-11	G1 Therapeutics, Inc.	G1t38 superior dosage regimes
CA3092907A1 (en) *	2018-03-05	2019-09-12	Klinikum Rechts Der Isar Der Technischen Universitat Munchen	Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor
CN111184863B (zh) *	2018-11-15	2023-06-16	江苏恒瑞医药股份有限公司	酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途
US10988479B1 (en)	2020-06-15	2021-04-27	G1 Therapeutics, Inc.	Morphic forms of trilaciclib and methods of manufacture thereof
KR102861622B1 (ko) *	2021-07-06	2025-09-18	국립암센터	Cdk4/6 억제제 및 삼환계 항우울제를 포함하는 암의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7196078B2 (en) *	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) *	2002-09-04	2014-03-18	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PT2316831E (pt)	2002-11-21	2013-06-06	Novartis Ag	2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
JO3235B1 (ar)	2006-05-26	2018-03-08	Astex Therapeutics Ltd	مركبات بيررولوبيريميدين و استعمالاتها
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
CN101981036B (zh)	2008-02-06	2013-09-04	诺瓦提斯公司	吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途
ES2522346T3 (es) *	2008-08-22	2014-11-14	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de CDK
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CN104987321A (zh)	2010-10-01	2015-10-21	诺华有限公司	制造嘧啶衍生物的方法
US20120115878A1 (en)	2010-11-10	2012-05-10	John Vincent Calienni	Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
JP5832647B2 (ja) *	2011-07-01	2015-12-16	ノバルティスアーゲー	がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
HK1211475A1 (en) *	2012-11-28	2016-05-27	Novartis Ag	Combination therapy

2012
- 2012-07-02 JP JP2014519218A patent/JP5832647B2/ja not_active Expired - Fee Related
- 2012-07-02 BR BR112013033940A patent/BR112013033940A2/pt not_active IP Right Cessation
- 2012-07-02 EP EP12735408.2A patent/EP2726074B1/en active Active
- 2012-07-02 AU AU2012279117A patent/AU2012279117A1/en not_active Abandoned
- 2012-07-02 WO PCT/US2012/045199 patent/WO2013006532A1/en not_active Ceased
- 2012-07-02 PH PH1/2013/502697A patent/PH12013502697A1/en unknown
- 2012-07-02 UA UAA201314209A patent/UA114178C2/uk unknown
- 2012-07-02 EA EA201490194A patent/EA030465B1/ru not_active IP Right Cessation
- 2012-07-02 CN CN201280032544.5A patent/CN103635189B/zh not_active Expired - Fee Related
- 2012-07-02 CA CA2840754A patent/CA2840754A1/en not_active Abandoned
- 2012-07-02 MY MYPI2013004386A patent/MY161237A/en unknown
- 2012-07-02 ES ES12735408.2T patent/ES2676180T3/es active Active
- 2012-07-02 PE PE2013002911A patent/PE20141381A1/es active IP Right Grant
- 2012-07-02 US US14/124,753 patent/US9271988B2/en active Active
- 2012-07-02 KR KR1020137034740A patent/KR20140040770A/ko not_active Abandoned
- 2012-07-02 MX MX2013015370A patent/MX359406B/es active IP Right Grant
2013
- 2013-12-06 TN TNP2013000508A patent/TN2013000508A1/fr unknown
- 2013-12-09 ZA ZA2013/09241A patent/ZA201309241B/en unknown
- 2013-12-09 IL IL229876A patent/IL229876B/en active IP Right Grant
- 2013-12-20 CO CO13297787A patent/CO6842016A2/es unknown
- 2013-12-20 GT GT201300320A patent/GT201300320A/es unknown
- 2013-12-26 MA MA36616A patent/MA35210B1/fr unknown
- 2013-12-31 CL CL2013003805A patent/CL2013003805A1/es unknown
2015
- 2015-08-17 JP JP2015160531A patent/JP2016027043A/ja active Pending
2016
- 2016-01-22 US US15/003,860 patent/US10010552B2/en active Active
- 2016-04-08 AU AU2016202213A patent/AU2016202213A1/en not_active Abandoned
2017
- 2017-09-21 AU AU2017232162A patent/AU2017232162B2/en not_active Ceased

Also Published As

Publication number	Publication date
AU2012279117A1 (en)	2014-01-09
UA114178C2 (uk)	2017-05-10
TN2013000508A1 (en)	2015-03-30
EA201490194A1 (ru)	2014-04-30
ES2676180T3 (es)	2018-07-17
JP2016027043A (ja)	2016-02-18
EP2726074B1 (en)	2018-04-04
GT201300320A (es)	2016-03-01
CN103635189B (zh)	2016-05-04
KR20140040770A (ko)	2014-04-03
AU2016202213A1 (en)	2016-05-05
MX359406B (es)	2018-09-27
CA2840754A1 (en)	2013-01-10
US9271988B2 (en)	2016-03-01
AU2017232162B2 (en)	2019-03-07
EP2726074A1 (en)	2014-05-07
ZA201309241B (en)	2014-08-27
PH12013502697A1 (en)	2014-02-10
JP2014518279A (ja)	2014-07-28
AU2017232162A1 (en)	2017-10-12
MX2013015370A (es)	2014-02-11
CO6842016A2 (es)	2014-01-20
MY161237A (en)	2017-04-14
WO2013006532A1 (en)	2013-01-10
MA35210B1 (fr)	2014-06-02
US10010552B2 (en)	2018-07-03
CN103635189A (zh)	2014-03-12
JP5832647B2 (ja)	2015-12-16
US20160136171A1 (en)	2016-05-19
US20140107114A1 (en)	2014-04-17
IL229876B (en)	2018-10-31
PE20141381A1 (es)	2014-10-21
BR112013033940A2 (pt)	2017-02-14
EA030465B1 (ru)	2018-08-31

Publication	Publication Date	Title
CL2013003805A1 (es)	2014-08-08	Combinación que comprende un primer agente que es un inhibidor de cinasa 4 dependiente de ciclina o cinasa 6 dependiente de ciclina (cdk4/6) de fórmula a y un segundo agente que es un inhibidor de pi3 cinasa de fórmula b1 o b2; uso para tratar cáncer.
CL2013001093A1 (es)	2013-09-27	Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2011000603A1 (es)	2011-07-29	Uso de compuestos de ditiina-tetracarboximidas que sirven para combatir hongos fitopatogenos; procedimiento para combatir dichos hongos; compuestos de ditiina-tetracarboximidas; uso de compuestos de ditiina-diisoimidas; y compuestos ditiina-diisoimidas.
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
BR112015007083A2 (pt)	2017-07-04	inibidores de histona demetilases
BR112015020650A2 (pt)	2017-07-18	inibidores de histona demetilases
ECSP15014941A (es)	2016-01-29	Compuestos antivíricos para el vsr
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
BR112016015449A8 (pt)	2020-06-09	compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112015026006A8 (pt)	2020-01-14	composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
CL2012003281A1 (es)	2013-05-17	Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
BR112017003433A2 (pt)	2017-11-28	inibidores espirocíclicos de catepsina c
CR20130267A (es)	2013-10-04	Inhibidores de nampt y rock
BR112017002214A2 (pt)	2018-01-16	composto de fórmula (i), composição farmacêutica e usos de um composto
CL2011002595A1 (es)	2013-10-04	Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion.
BR112016027041A8 (pt)	2021-07-20	combinações farmacêuticas para tratamento do câncer
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2008000029A1 (es)	2008-04-04	Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI1009781A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
UY37015A (es)	2017-06-30	Inhibidores de la tirosina quinasa de bruton y métodos de su uso
BR112015022092A8 (pt)	2018-01-23	derivado de di-hidropiridazina-3,5-diona, seu uso e agente preventivo e/ou terapêutico comprendendo o mesmo
CL2014002986A1 (es)	2015-01-09	Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
BR112018011525A2 (pt)	2018-11-21	inibidores da tirosina quinase de bruton e métodos de seu uso
BR112016005589A8 (pt)	2018-02-06	composição farmacêutica líquida, e, uso da mesma
DOP2015000176A (es)	2015-11-15	Compuestos de azetidiniloxifenilpirrolidina